NEW YORK (360Dx) – OptiScan Biomedical today announced its OptiScanner 6000 device for near-continuous glucose and lactate monitoring has received CE mark, allowing the firm to market it in the European Union.

The Hayward, California-based firm said it plans to launch the device later this year.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.